To develop care processes and personalised cancer medicine by new technologies - A validation study of self-testing home-based capillary kit, the True Dose kit
| Reference number | |
| Coordinator | Region Stockholm - Karolinska Universitetssjukhuset |
| Funding from Vinnova | SEK 1 500 000 |
| Project duration | June 2025 - August 2027 |
| Status | Ongoing |
| Venture | Medtech4Health innovators |
| Call | Medtech4Health: Implementation of medical technology in healthcare in 2025 |
Purpose and goal
The aim is to validate a new home-based self-sampling test from True Dose, for therapeutic drug monitoring in patients with non-small cell lung cancer (NSCLC). The goal is to develop a care model that enables individualized dosing and follow-up at home, thereby improving adherence, reducing side effects, and increasing survival.
Expected effects and result
The project is expected to deliver technical and clinical validation of the True Dose kit and identify organizational requirements for implementation. The outcome will support improved treatment adherence, enhanced quality of life for patients, and more efficient healthcare resource use.
Planned approach and implementation
The project is a prospective, open, non-randomized single-center study to validate the True Dose kit for therapeutic drug monitoring in a home setting. It targets NSCLC patients treated with taxanes or ALK inhibitors. The project also evaluates logistical requirements, usability, and acceptance. A total of 40 patients will be included. Data will be collected via eCRF and analyzed using LC-MS/MS.